New therapeutic antibody for dog cancers

Anne Li                                                                                     August 26th, 2017                                   anne2001.li@gmail.com


In humans, some malignant cancer cells express PD-L1 proteins that bind to their receptor PD-1 on T cells, resulting in the suppression of the T cell's immune function. Thus, PD-L1/PD-1 interaction is considered an "immune escape mechanism" that cancer cells have. Antibodies that block PD-1/PD-L1 binding have proven effective in inducing anti-tumor immune responses and have been widely used in immunotherapy in the last five years. However, in dogs, no such clinical studies have been reported so far.


See original article at: https://www.sciencedaily.com/releases/2017/08/170825090640.htm

Post a comment